Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

30 Mar 2024

Abstract excerpt

BACKGROUND: Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated. METHODS: The production of functional viruses was assessed by immunoblotting and replication assays. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Glioma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38554031
DOI: 10.1093/neuonc/noae066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsPMID 38554031Read ↗

ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastomaSemantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

Gene Therapy for High Grade Glioma: The Clinical ExperienceSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical ModelsSemantic proximity Read ↗

Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatarsSemantic proximity Read ↗

Navitoclax acts synergistically with irradiation to induce apoptosis in preclinical models of H3K27M-altered diffuse midline glioma.Semantic proximity Read ↗

Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced ApoptosisSemantic proximity Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionSemantic proximity Read ↗

STINGing the immune system: lessons learned through a model of G34-mutant pediatric high-grade glioma.Semantic proximity Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.